Radius Health (NASDAQ:RDUS) had its price objective decreased by JPMorgan Chase & Co. from $70.00 to $60.00 in a research report report published on Monday. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

RDUS has been the subject of several other research reports. Cantor Fitzgerald reaffirmed a buy rating and issued a $58.00 target price on shares of Radius Health in a research report on Thursday, January 18th. ValuEngine raised Radius Health from a strong sell rating to a sell rating in a research report on Friday, December 1st. Citigroup reissued a hold rating and set a $43.00 price objective on shares of Radius Health in a research report on Monday, January 22nd. BidaskClub cut Radius Health from a sell rating to a strong sell rating in a research report on Thursday, December 7th. Finally, Zacks Investment Research cut Radius Health from a hold rating to a sell rating in a research report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $51.78.

Shares of Radius Health (RDUS) opened at $36.42 on Monday. The company has a market capitalization of $1,620.00, a price-to-earnings ratio of -6.71 and a beta of 1.21. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health has a 12-month low of $24.66 and a 12-month high of $49.16.

In other news, major shareholder Growth N. V. Biotech acquired 75,000 shares of Radius Health stock in a transaction that occurred on Friday, February 9th. The stock was purchased at an average price of $34.38 per share, with a total value of $2,578,500.00. Following the completion of the transaction, the insider now owns 5,773,799 shares in the company, valued at $198,503,209.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 15.00% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. Candriam Luxembourg S.C.A. lifted its position in shares of Radius Health by 23.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 142,000 shares of the biopharmaceutical company’s stock worth $5,474,000 after buying an additional 27,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Radius Health by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after buying an additional 135,071 shares during the last quarter. State Street Corp lifted its position in shares of Radius Health by 12.9% in the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after buying an additional 213,399 shares during the last quarter. BlackRock Inc. lifted its position in shares of Radius Health by 10.0% in the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after buying an additional 262,896 shares during the last quarter. Finally, Sei Investments Co. lifted its position in shares of Radius Health by 2,302.7% in the third quarter. Sei Investments Co. now owns 76,407 shares of the biopharmaceutical company’s stock worth $2,945,000 after buying an additional 73,227 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Trims Radius Health (RDUS) Target Price to $60.00” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/jpmorgan-chase-co-trims-radius-health-rdus-target-price-to-60-00/1862896.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.